C3 glomerulopathy and eculizumab: a report on four paediatric cases
- 24 February 2017
- journal article
- case report
- Published by Springer Nature in Pediatric Nephrology
- Vol. 32 (6) , 1023-1028
Abstract
Eculizumab may be used to treat C3-glomerulopathy (C3G), a rare but severe glomerular disease.Keywords
This publication has 15 references indexed in Scilit:
- Effectiveness of mycophenolate mofetil in C3 glomerulonephritisKidney International, 2015
- Primary disease recurrence—effects on paediatric renal transplantation outcomesNature Reviews Nephrology, 2015
- Insights From the Use in Clinical Practice of Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome Affecting the Native Kidneys: An Analysis of 19 CasesAmerican Journal of Kidney Diseases, 2014
- Impact of graft loss among kidney diseases with a high risk of post-transplant recurrence in the paediatric populationNephrology Dialysis Transplantation, 2013
- Successful Use of Eculizumab in a Pediatric Patient Treated for Paroxysmal Nocturnal HemoglobinuriaJournal of Pediatric Hematology/Oncology, 2012
- Eculizumab Treatment of Acute Antibody-Mediated Rejection in Renal Transplantation: Case ReportsTransplantation Proceedings, 2012
- Pathogenesis of the C3 glomerulopathies and reclassification of MPGNNature Reviews Nephrology, 2012
- Membranoproliferative Glomerulonephritis — A New Look at an Old EntityNew England Journal of Medicine, 2012
- Eculizumab for the Treatment of Dense-Deposit DiseaseNew England Journal of Medicine, 2012
- Remission of resistant MPGN type I with mycophenolate mofetil and steroidsPediatric Nephrology, 2009